# Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion

> **NCT03108352** · PHASE3 · COMPLETED · sponsor: **Chengdu Kanghong Biotech Co., Ltd.** · enrollment: 255 (actual)

## Conditions studied

- Branch Retinal Vein Occlusion
- Macular Edema

## Interventions

- **DRUG:** Conbercept ophthalmic injection
- **OTHER:** sham/Conbercept ophthalmic injection

## Key facts

- **NCT ID:** NCT03108352
- **Lead sponsor:** Chengdu Kanghong Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-13
- **Primary completion:** 2020-04-13
- **Final completion:** 2020-10-16
- **Target enrollment:** 255 (ACTUAL)
- **Last updated:** 2022-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03108352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03108352, "Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03108352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*